Bioabsorbable Stent Market—By Material: Polymer-Based Stents, Metal-Based Stents; By Absorption Rate: Fast Absorbing, Slow Absorbing; By Application: Coronary Artery Disease, Peripheral Artery Disease; By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers; By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
Market Overview
The bioabsorbable stent market includes next-generation cardiovascular devices designed to temporarily support arteries before gradually dissolving in the body. These stents are particularly important in treating coronary artery disease (CAD), as they aim to minimize long-term complications like in-stent restenosis and late thrombosis associated with traditional metallic stents. Made from biodegradable polymers such as polylactic acid or magnesium alloys, these stents promote better vascular healing and eliminate the need for permanent implants.
Despite initial challenges with first-generation bioresorbable stents, the market is gaining momentum through the development of newer, safer designs and increasing demand for minimally invasive, temporary cardiovascular solutions.
Market Size and Forecast
|
Year |
Market Value (USD Billion) |
Notes |
|
2019 |
0.62 |
Early adoption phase; limited regulatory approvals |
|
2024 |
1.08 |
Resurgence driven by new product launches and EU/Asia uptake |
|
2031 |
2.45 |
CAGR 12.6% (2024–2031) |
By 2031, growing regulatory support and clinical validation are expected to propel the global market past USD 2.4 billion.
Primary Market Drivers
• Rising global burden of coronary artery disease and lifestyle-related conditions
• Growing interest in device-free arterial restoration therapies
• Technological advancements in polymer degradation and structural integrity
• Increasing clinical trials and favorable reimbursement pilot programs
• Preference among younger patient cohorts for resorbable treatment options
Market Challenges
• Safety concerns from earlier generation stents with higher thrombosis risk
• Regulatory scrutiny over long-term clinical endpoints
• Higher costs compared to conventional drug-eluting stents (DES)
• Limited training and familiarity among interventional cardiologists
• Variability in stent degradation timelines under different patient conditions
Competitive Landscape
|
Company / Organization |
2024 Share |
Core Strengths |
Recent Moves |
|
Abbott |
24 % |
Absorb GT1 stent, robust clinical data |
Relaunched bioabsorbable line with improved coating (Q2 2024) |
|
BIOTRONIK |
19 % |
Magnesium-based resorbable stents |
Expanded CE-marked product to LATAM markets (Q1 2025) |
|
Reva Medical |
12 % |
Radiopaque polymer stents |
Partnered with Japan cardiology centers (Q3 2024) |
|
Amaranth Medical |
7 % |
Drug-eluting PLLA scaffold technology |
Began pivotal trials in EU (Q4 2024) |
|
Others (Elixir, Zorion Medical, academic spinouts) |
38 % |
Niche material innovations, regional sales |
Collaborations with CROs and local medtech hubs |
Detailed Market Segmentation
By Material
• Poly-L-lactic Acid (PLLA) – 41 %
• Magnesium Alloys – XX %
• Poly-D,L-lactide (PDLLA) – XX %
• Others (Zinc, Composite Polymers) – XX %
By Application
• Coronary Artery Disease – 78 %
• Peripheral Artery Disease – XX %
• Bioresorbable Scaffold Research – XX %
By End User
• Hospitals – 54 %
• Cardiac Specialty Clinics – XX %
• Research & Clinical Trial Centers – XX %
Regional Analysis
• North America (34%) – Slower uptake due to FDA caution, but growing off-label use and trial expansions
• Europe (31%) – Leading clinical research and usage, particularly in Germany and France
• Asia-Pacific (XX%) – Strong growth from Japan, India, and China due to aging populations and procedure volume
• Latin America & MEA (9%) – Nascent markets supported by government pilot trials and NGO partnerships
Technology and Innovation
• Radiopaque scaffolds enabling real-time imaging during placement
• Optimized drug-polymer combinations for anti-inflammatory effects
• Dual-layer biodegradable structures for staged dissolution
• Machine learning algorithms for predicting stent resorption dynamics
• Bioresorbable scaffolds combined with gene therapy agents under trial
Regulatory Environment
• CE Mark renewals for multiple EU bioabsorbable platforms
• FDA breakthrough designation for new-generation magnesium scaffolds
• ISO 25539 compliance for cardiovascular implants
• China’s NMPA fast-tracks resorbable stents under innovation pathways
Recent Developments (Q4 2023 – Q2 2025)
• Abbott launched next-gen bioresorbable stent in Europe (Q2 2024)
• BIOTRONIK’s MAGNITUDE scaffold approved in Brazil (Q1 2025)
• Reva Medical’s Fantom Encore received Japan trial nod (Q3 2024)
• Amaranth initiated multi-site pivotal study in EU (Q4 2024)
• WHO and Gates Foundation announced global CAD pilot using resorbables (Q2 2025)
Strategic Outlook
• Market players must invest in post-market surveillance and long-term outcome data
• Educating cardiologists on optimal deployment techniques is key to adoption
• Reimbursement strategies will hinge on cost-effectiveness and safety proof
• Cross-disciplinary R&D in materials science and pharmacology will fuel next-gen products
Methodology
Clearview Market Insights aggregated data from interventional cardiology procedures, clinical trial registries, and procurement logs across 26 countries. Forecast models include trends in CAD incidence, treatment guidelines, and stent lifecycle metrics.
About Clearview Market Insights
Clearview Market Insights delivers expert data and analysis across cardiovascular devices, structural heart innovation, and emerging biodegradable materials in interventional medicine.
• Benchmark next-gen biodegradable stent platforms and performance metrics
• Track evolving regulations and reimbursement for temporary scaffolds
• Analyze regional cardiovascular intervention trends and product adoption
• Explore innovation in polymer science and smart stent integration
• Historic and projected revenue (2019–2031) for bioabsorbable stents
• Segmentation by material, application, and end user
• Regulatory and innovation analysis for key regions
• Profiles of key players and clinical development pipelines
Need help?
Chat with our team in a minute.